Fig. 8: Tfam deletion in B cells prevents lymphoma.

a, Schematic depicting the adoptive transfer strategy of lymphoma cells from Eμ-Myc mice. After the development of lymphoma, cells were transferred into WT congenic (CD45.1⁺) recipients. Representative flow cytometry plots showing the identification of CD19⁺CD45.2⁺ donor lymphoma cells and CD19⁺CD45.1⁺ WT B cells from the inguinal lymph nodes of recipient mice after 3 weeks. b, Flow cytometry histogram plot depicting COXI expression in CD45.2⁺ lymphoma cells and CD45.2⁻ WT B cells (n = 5 mice) as described in a. FMO, fluorescence minus one. Quantification of COXI gMFI. Data are representative of two independent experiments. c, Flow cytometry histogram depicting TFAM expression in CD45.2⁺ lymphoma cells and CD45.1⁺ WT B cells (n = 5 mice) as described in a. Quantification of TFAM gMFI. Data are representative of two independent experiments. d, Kaplan–Meier graph depicting the survival curve of Eμ-Myc × Tfam homozygous (Cd79a^Cre/+Tfam^loxP/loxP × Eμ-Myc, n = 9), Eμ-Myc Tfam heterozygous (Cd79a^Cre/+Tfam^loxP/+ × Eμ-Myc, n = 13) and Eμ-Myc (Cd79a^+/+Tfam^loxP/loxP × Eμ-Myc or Cd79a^+/+Tfam^loxP/+ × Eμ-Myc, n = 18) mice followed for up to 6 months of age. e, Representative flow cytometry histogram depicting COXI expression in the Daudi cell line treated with the IMT1 at various concentrations (0.1 μM, 1 μM, 10 μM) or vehicle (DMSO) for 120 h. Representative of three independent experiments. f, Quantification of COXI levels by flow cytometry, normalized to SDHB in IMT1- or vehicle-treated Daudi cells at different concentrations and time points (0, 24, 48, 72, 96, 120 h), representative of two independent experiments. g, Airyscan ICC confocal images of COXI and TOMM20 in Daudi cells treated with DMSO or IMT1 (1 μM) for 120 h. Scale bar, 3 μm. Representative of two independent experiments. h, Quantification of live Daudi cell concentrations over a 120-h incubation period in the presence of IMT1 or vehicle (DMSO), representative of two independent experiments with three to five technical replicates each. i, Flow cytometry-based quantification of mtROS in the Daudi cell line treated with IMT1 (1 μM) or vehicle (DMSO) for 120 h. Each point represents technical replicates (n = 3 per group). Representative of two independent experiments. j, Airyscan confocal images of Daudi cells treated with IMT1 (1 μM) or DMSO and stained for F-actin phalloidin. Scale bar, 5 μm. Representative of two independent experiments. k, Quantification of F-actin phalloidin fluorescence by flow cytometry (n = 5 technical replicates). Data are representative of two independent experiments. l, Quantification of COXI levels in Daudi cells by flow cytometry after treatment with vehicle (ethanol) or CHL at 10 μg ml⁻¹ or 25 μg ml⁻¹ for 120 h (n = 8 technical replicates). Data are representative of two independent experiments. m, Quantification of F-actin levels in Daudi cells by flow cytometry after treatment with vehicle (ethanol) or CHL at 10 μg ml⁻¹ or 25 μg ml⁻¹ for 120 h (n = 8 technical replicates). Data are representative of two independent experiments. n, Quantification of live Daudi cell concentrations over a 120-h incubation period in the presence of CHL at 10 μg ml⁻¹ or 25 μg ml⁻¹ or vehicle (ethanol) as in m. Representative of two independent experiments with four technical replicates (n = 4). Statistical significance was calculated using an unpaired two-tailed t-test (b,c,i), a Mantel–Cox log-rank test (d) or an ordinary one-way ANOVA with Tukey’s (h,n) or Dunnett’s multiple comparisons test (k–m). Data are presented as the mean ± s.e.m.

Source data